Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis

Abstract Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This exploratory study was designed to evaluate the treatment effect of...

Full description

Bibliographic Details
Main Authors: Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Thoracic Cancer
Subjects:
cross‐resistance
lung cancer
Pemetrexed
S‐1
Online Access:https://doi.org/10.1111/1759-7714.14055

Internet

https://doi.org/10.1111/1759-7714.14055

Similar Items